natgillin/translations-raw huggingface dataset:
Co-administration af tadalafil til behandling af pulmonal arteriel hypertension, darunavir og lavdosis ritonavir anbefales ikke. 
Co-administration of tadalafil for the treatment of pulmonary arterial hypertension with darunavir and low dose ritonavir is not recommended.
Lopinavir/ritonavir 400/100 mg to gange daglig 
Lopinavir/ritonavir 400/100 mg twice daily
Klinisk monitorering anbefales ved co-administration af boostet darunavir med disse antidepressiva, og det kan være nødvendigt at justere dosis af antidepressivummet. 
Clinical monitoring is recommended when co-administering boosted darunavir with these antidepressants and a dose adjustment of the antidepressant may be needed.
Lever og galdeveje almindelig forhøjet alanin-aminotranferase ikke almindelig hepatitis, cytolytisk hepatitis, hepatisk steatose, hepatomegali, forhøjet aminotransferase, forhøjet aspartat-aminotranferase, forhøjet bilirubin i blodet, forhøjet alkalisk phosphatase i blodet, forhøjet gamma-glutamyltransferase 
Hepatobiliary disorders common increased alanine aminotransferase uncommon hepatitis, cytolytic hepatitis, hepatic steatosis, hepatomegaly, increased transaminase, increased aspartate aminotransferase, increased blood bilirubin, increased blood alkaline phosphatase, increased gamma-glutamyltransferase
Warfarinkoncentrationer kan blive påvirket ved samtidig administration af boostet darunavir. 
Warfarin concentrations may be affected when co-administered with boosted darunavir.
Anvisninger for børn - Barnet skal altid tage Darunavir Krka sammen med ritonavir. 
The child must take Darunavir Krka always together with ritonavir.
Darunavir Krka med ritonavir er ikke blevet testet med alle proteasehæmmere og må ikke bruges med andre hiv-proteasehæmmere. 
Darunavir Krka with ritonavir has not been tested with all PIs (protease inhibitors) and must not be used with other HIV PIs.
ÆSKE 
BOX
Eksponeringen for disse immunsuppressiva vil øges ved samtidig administration af darunavir co-administreret med lavdosis ritonavir. 
Exposure to these immunosuppressants will be increased when co-administered with darunavir coadministered with low dose ritonavir.
Darunavir Krka, administreret sammen med lavdosis ritonavir, er i kombination med andre antiretrovirale lægemidler indiceret til behandling af patienter med human immundefektvirus (hiv-1)-infektion (se pkt. 
Darunavir Krka, co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV-1) infection (see section 4.2).
Interaktionsprofilen for darunavir er afhængig af, om ritonavir benyttes som farmakokinetisk forstærker. 
The interaction profile of darunavir depends on whether ritonavir is used as pharmacokinetic enhancer.
Darunavir metaboliseres især via CYP3A. 
Darunavir is primarily metabolised by CYP3A.
Lægemidler, som påvirker darunavireksponering (cobicistat som farmakoforstærker) 
Medicinal products that affect darunavir exposure (cobicistat as pharmacoenhancer)
Det anbefales ikke at coadministrere boostet darunavir og boceprevir. 
It is not recommended to coadminister boosted darunavir and boceprevir.
Det er ikke nødvendigt at justere metadondosis, når der påbegyndes behandling med darunavir/ritonavir. 
No adjustment of methadone dosage is required when initiating coadministration with darunavir /ritonavir.
Tenofovirdisoproxil 245 mg en gang daglig tenofovir AUC ↑ 22% tenofovir Cmin ↑ 37% tenofovir Cmax ↑ 24% darunavir AUC ↑ 21% darunavir Cmin ↑ 24% darunavir Cmax ↑ 16% (↑ tenofovir fra effekten på MDR-1 transport i de renale tubuli) 
Tenofovir disoproxil 245 mg once daily tenofovir AUC ↑ 22% tenofovir Cmin ↑ 37% tenofovir Cmax ↑ 24% darunavir AUC ↑ 21% darunavir Cmin ↑ 24% darunavir Cmax ↑ 16% (↑ tenofovir from effect on MDR-1 transport in the renal tubules)
Efter behandlingen er påbegyndt, må du ikke ændre dosis eller lægemiddelform eller afbryde behandlingen uden først at tale med lægen. 
After therapy has been initiated, the dose or dosage form must not be changed or therapy must not be stopped without instruction of the doctor.
Der skal udvises forsigtighed, når clarithromycin kombineres med boostet darunavir. 
Caution should be exercised when clarithromycin is combined with boosted darunavir.
Warfarinkoncentrationer kan blive påvirket ved samtidig administration af darunavir med lavdosis ritonavir. 
Warfarin concentrations may be affected when co-administered with darunavir with low dose ritonavir.
Sertralin 50 mg en gang daglig paroxetin AUC ↓ 39% paroxetin Cmin ↓ 37% paroxetin Cmax ↓ 36% darunavir AUC ↔ darunavir Cmin ↔ darunavir Cmax ↔ sertralin AUC ↓ 49% sertralin Cmin ↓ 49% sertralin Cmax ↓ 44% darunavir AUC ↔ darunavir Cmin ↓ 6% darunavir Cmax ↔ 
Amitriptyline Desipramine Imipramine Nortriptyline Trazodone paroxetine AUC ↓ 39% paroxetine Cmin ↓ 37% paroxetine Cmax ↓ 36% darunavir AUC ↔ darunavir Cmin ↔ darunavir Cmax ↔ sertraline AUC ↓ 49% sertraline Cmin ↓ 49% sertraline Cmax ↓ 44% darunavir AUC ↔ darunavir Cmin ↓ 6% darunavir Cmax ↔
I 96-ugers-analysen svarede sikkerhedsprofilen for darunavir/ritonavir 800/100 mg en gang daglig hos behandlingsnaive patienter til profilen for darunavir/ritonavir 600/100 mg to gange daglig hos behandllingserfarne patienter med undtagelse af kvalme, der sås hyppigere hos behandlingsnaive patienter. 
In the 96 week analysis, the safety profile of darunavir/ritonavir 800/100 mg once daily in treatmentnaïve subjects was similar to that seen with darunavir/ritonavir 600/100 mg twice daily in treatmentexperienced subjects except for nausea which was observed more frequently in treatment-naïve subjects.
Der blev ikke observeret nogen krydsresistens med andre PI i de virologiske svigt fra ARTEMIS-studiet. 
In the virologic failures of the ARTEMIS trial no cross-resistance with other PIs was observed.
Der skal udvises forsigtighed, og om muligt anbefales monitorering af terapeutisk koncentration for disse antiarytmika ved coadministration med boostet darunavir. 
Caution is warranted and therapeutic concentration monitoring, if available, is recommended for these antiarrhythmics when coadministered with boosted darunavir.
Klinisk monitorering for centralnervesystemstoksicitet i forbindelse med øget eksponering for efavirenz kan være indiceret, når darunavir administreres sammen med lavdosis ritonavir gives i kombination med efavirenz. 
Clinical monitoring for central nervous system toxicity associated with increased exposure to efavirenz may be indicated when darunavir coadministered with low dose ritonavir is given in combination with efavirenz.
Darunavir/ritonavir bør kun anvendes under graviditet, hvis den mulige fordel opvejer den mulige risiko. 
Darunavir/ritonavir should be used during pregnancy only if the potential benefit justifies the potential risk.
Det reproduktive system og mammae ikke almindelig gynækomasti* 
Reproductive system and breast disorders uncommon gynaecomastia*
Co-administration af darunavir co-administreret med cobicistat og rifabutin frarådes. 
Co-administration of darunavir coadministered with cobicistat and rifabutin is not recommended.
ART-erfarne pædiatriske patienter i alderen 6 til <18 år og legemsvægt på mindst 20 kg 
ART-experienced paediatric patients (3 to 17 years of age and weighing at least 40 kg)
Systemisk dexamethason skal bruges med forsigtighed ved kombination med darunavir administreret sammen med lavdosis ritonavir. 
Systemic dexamethasone should be used with caution when combined with darunavir co-administered with low dose ritonavir.
ANTIEPILEPTIKA Phenobarbital Phenytoin 
ANTICONVULSANTS Phenobarbital Phenytoin
Plasmakoncentrationen af disse lægemidler kan øges ved samtidig administration af boostet darunavir, hvilket medfører nedsat serumcortisol. 
Plasma concentrations of these medicinal products may be increased when co-administered with boosted darunavir, resulting in reduced serum cortisol concentrations.
Darunavir Krka skal tages i kombination med en lav dosis ritonavir og anden hivmedicin. 
Darunavir Krkamust be taken in combination with a low dose of ritonavir and other anti-HIV medicines.
Rilpivirin 150 mg en gang daglig rilpivirin AUC ↑ 130% rilpivirin Cmin ↑ 178% rilpivirin Cmax ↑ 79% darunavir AUC ↔ darunavir Cmin ↓ 11% darunavir Cmax ↔ 
Rilpivirine 150 mg once daily rilpivirine AUC ↑ 130% rilpivirine Cmin ↑ 178% rilpivirine Cmax ↑ 79% darunavir AUC ↔ darunavir Cmin ↓ 11% darunavir Cmax ↔
Er du i tvivl, så spørg lægen apotekspersonalet eller sygeplejersken. 
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Co-administration af parenteral midazolam med darunavir coadministreret med lavdosis ritonavir kan give en kraftig forøgelse af koncentrationen af dette benzodiazepin. 
If parenteral midazolam is co-administered with darunavir co-administered with low dose ritonavir it may cause a large increase in the concentration of this benzodiazepine.
- Tag altid Darunavir Krka sammen med 100 mg ritonavir. 
Take Darunavir Krka always together with 100 milligram of ritonavir.
Saquinavir 1.000 mg to gange daglig darunavir AUC ↓ 26% darunavir Cmin ↓ 42% darunavir Cmax ↓ 17% saquinavir AUC ↓ 6% saquinavir Cmin ↓ 18% saquinavir Cmax ↓ 6% 
Saquinavir 1,000 mg twice daily darunavir AUC ↓ 26% darunavir Cmin ↓ 42% darunavir Cmax ↓ 17% saquinavir AUC ↓ 6% saquinavir Cmin ↓ 18% saquinavir Cmax ↓ 6%
Disse omfatter: 
The dose is either:
Plasmakoncentrationen af disse lægemidler kan øges ved samtidig administration af darunavir med lavdoisis ritonavir, hvilket medfører nedsat serumcortisol. 
Plasma concentrations of these medicinal products may be increased when co-administered with darunavir with low dose ritonavir, resulting in reduced serum cortisol concentrations.
Darunavir Krka er tilgængelig i beholdere indeholdende 30 filmovertrukne tabletter (1 beholder med 30 filmovertrukne tabletter), 60 filmovertrukne tabletter (2 beholdere med 30 filmovertrukne tabletter), 90 filmovertrukne tabletter (3 beholdere med 30 filmovertrukne tabletter) og 180 filmovertrukne tabletter (6 beholdere med 30 filmovertrukne tabletter) i en æske. 
Darunavir Krka is available in bottles containing 30 film-coated tablets (1 bottle of 30 film-coated tablets), 60 film-coated tablets (2 bottles of 30 film-coated tablets), 90 film-coated tablets (3 bottles of 30 film-coated tablets) and 180 film-coated tablets (6 bottles of 30 film-coated tablets) in a boxes.
Darunavir coadministereret med lavdosis ritonavir kan forventes at øge plasmakoncentrationen af calciumantagonisterne. 
Darunavir co-administered with low dose ritonavir can be expected to increase the plasma concentrations of calcium channel blockers.
Samtidig brug af darunavir med lavdoisis ritonavir og kortikosteroider, der metaboliseres via CYP3A (f.eks. fluticasonpropionat eller andre inhalerede eller nasale kortikosteroider) kan øge risikoen for systemiske kortikosteroidbivirkninger, herunder Cushings syndrom og binyresuppression. 
Concomitant use of darunavir with low dose ritonavir and corticosteroids that are metabolised by CYP3A (e.g. fluticasone propionate or other inhaled or nasal corticosteroids) may increase the risk of development of systemic corticosteroid effects, including Cushing's syndrome and adrenal suppression.
Se Produktresuméet for Darunavir Krka 600 mg tabletter (se pkt. 
See the Summary of Product Characteristics for Darunavir Krka 600 mg tablets (see section 4.5).
Se doseringsanbefalingerne til ART-naive patienter se produktresuméet for Darunavir Krka 400 mg og 800 mg tabletter. 
For dosage recommendations in ART-naïve patients see the Summary of Product Characteristics for Darunavir Krka 400 mg and 800 mg tablets.
Selvom effekten på CYP2C8 kun er blevet undersøgt in vitro, kan co-administration af darunavir og ritonavir og lægemidler, som primært metaboliseres af CYP2C8 (såsom paclitaxel, rosiglitazon, repaglinid), resultere i nedsat systemisk eksponering af disse lægemidler, hvilken kan nedsætte eller forkorte deres terapeutiske effekt. 
Although the effect on CYP2C8 has only been studied in vitro, co-administration of darunavir and ritonavir and medicinal products primarily metabolised by CYP2C8 (such as paclitaxel, rosiglitazone, repaglinide) may result in decreased systemic exposure to such medicinal products, which could decrease or shorten their therapeutic effect.
Darunavir skal altid gives oralt med lavdosis ritonavir som en farmakokinetisk forstærker og i kombination med andre antiretrovirale lægemidler. 
Darunavir must always be given orally with low dose ritonavir as a pharmacokinetic enhancer and in combination with other antiretroviral medicinal products.
Postpartum (6-12 uger) (n = 6) 
Postpartum (6-12 weeks) (n=6)
Darunavir Krka 400 mg filmovertrukne tabletter er tilgængelige i beholdere indeholdende 30 filmovertrukne tabletter (1 beholder med 30 filmovertrukne tabletter), 60 filmovertrukne tabletter (2 beholdere med 30 filmovertrukne tabletter), 90 filmovertrukne tabletter (3 beholdere med 30 filmovertrukne tabletter) og 180 filmovertrukne tabletter (6 beholdere med 30 filmovertrukne tabletter) i en æske. 
Darunavir Krka 400mg film-coated tabletsareavailable in bottlescontaining 30 film-coated tablets (1 bottleof 30 film-coated tablets), 60 film-coated tablets (2 bottlesof 30 film-coated tablets), 90 filmcoated tablets (3 bottlesof 30 film-coated tablets)and 180 film-coated tablets (6 bottlesof 30 filmcoated tablets)in a box.
Brug af carbamazepin sammen med darunavir co-administreret med cobicistat er kontraindiceret (se pkt. 
The use of carbamazepine with darunavir co-administered with cobicistat is contraindicated (see section 4.3).
Mave-tarm-kanalen meget almindelig diarré, kvalme almindelig opkastning, mavesmerter, abdominal distension, dyspepsi, flatulens, forhøjede pancreas-enzymer ikke almindelig akut pancreatitis 
Gastrointestinal disorders very common diarrhoea, nausea common vomiting, abdominal pain, abdominal distension, dyspepsia, flatulence, pancreatic enzymes increased uncommon pancreatitis acute
Med CD4+celletal (× 10 
With Baseline CD4+ cell count (x 10
Der kan derfor være forskellige anbefalinger for darunavir og samtidige lægemidler afhængigt af, om darunavir er boostet med ritonavir eller cobicistat. 
Darunavir may therefore have different recommendations for concomitant medications depending on whether the compound is boosted with ritonavir or cobicistat.
Det reproduktive system og mammae ikke almindelig erektil dysfunktion, gynækomasti 
Reproductive system and breast disorders uncommon erectile dysfunction, gynaecomastia
Cobicistat og ritonavir-hæmmer CYP3A, hvilket øger plasmakoncentrationen af darunavir betragteligt. 
Cobicistat and ritonavir inhibit CYP3A, thereby increasing the plasma concentrations of darunavir considerably.
Co-administration af boostet darunavir og naloxegol er kontraindiceret. 
Co-administration of boosted darunavir and naloxegol is contraindicated.
Avanafil til behandling af impotens 
Avanafil to treat erectile dysfunction
Cmax, ng/ml AUC24t, ng∙t/ml Cmin, ng/ml 
Cmax, ng/mL AUC24h, ng.h/mL Cmin, ng/mL
Darunavir Krka kan forhøje blodsukkerniveauet. 
Darunavir Krka might increase sugar levels in the blood.
NATURLÆGEMIDLER Perikon (Hypericum perforatum) 
HERBAL PRODUCTS St John's wort (Hypericum perforatum)
4.2 påvirkede ikke koncentrationen af darunavir i signifikant grad. 
Increasing the dose of ritonavir from that recommended in section 4.2 did not significantly affect darunavir concentrations.
Derfor kan den samme daglige dosis anvendes til behandlingserfarne unge i alderen 12 til <18 år med en legemsvægt på mindst 40 kg, der ikke har mutationer associeret med darunavirresistens (DRV-RAMs)*, og som har plasma-hiv-1-RNA <100.000 kopier/ml og CD4+-celletal ≥100 × 10 
Therefore the same once daily dosage may be used in treatment-experienced adolescents aged 12 to < 18 years and weighing at least 40 kg without darunavir resistance associated mutations (DRV-RAMs)* and who have plasma HIV-1 RNA < 100,000 copies/ml and CD4+ cell count ≥ 100 cells x 10
Lægemidler, der inducerer CYP3Aaktivitet, ville forventes at øge clearance af darunavir og ritonavir, hvilket medfører en lavere plasmakoncentration af darunavir og ritonavir (f.eks. rifampicin, perikon, lopinavir). 
Medicinal products that induce CYP3A activity would be expected to increase the clearance of darunavir and ritonavir, resulting in lowered plasma concentrations of darunavir and ritonavir (e.g. rifampicin, St John's wort, lopinavir).
ØSTROGENBASERET PRÆVENTION Drospirenon 
OESTROGEN-BASED CONTRACEPTIVES Drospirenone
Indinavir 800 mg to gange daglig indinavir AUC ↑ 23% indinavir Cmin ↑ 125% indinavir Cmax ↔ darunavir AUC ↑ 24% darunavir Cmin ↑ 44% darunavir Cmax ↑ 11% 
Indinavir 800 mg twice daily indinavir AUC ↑ 23% indinavir Cmin ↑ 125% indinavir Cmax ↔ darunavir AUC ↑ 24% darunavir Cmin ↑ 44% darunavir Cmax ↑ 11%
Co-administration af darunavir og ritonavir med andre lægemidler, som hæmmer CYP3A, kan nedsætte clearance af darunavir og ritonavir, hvilket kan medføre øgede plasmakoncentrationer af darunavir og ritonavir (f.eks. indinavir, azol antimykotika som clotrimazol). 
Co-administration of darunavir and ritonavir and other medicinal products that inhibit CYP3A may decrease the clearance of darunavir and ritonavir and may result in increased plasma concentrations of darunavir and ritonavir (e.g. indinavir, azole antifungals like clotrimazole).
Plasmakoncentrationen af lovastatin og simvastatin forventes at stige markant, når de gives sammen med darunavir coadministreret med lavdosis ritonavir. 
Lovastatin and simvastatin are expected to have markedly increased plasma concentrations when coadministered with darunavir coadministered with low dose ritonavir.
Interaktionsstudiet viste en sammenlignelig daglig systemisk eksponering af rifabutin imellem behandling med 300 mg en gang daglig og 150 mg hver anden dag i kombination med darunavir/ritonavir (600/100 mg to gange daglig). 
The interaction trial showed a comparable daily systemic exposure for rifabutin between treatment at 300 mg once daily alone and 150 mg once every other day in combination with darunavir/ritonavir (600/100 mg twice daily) with an about 10fold increase in the daily exposure to the active metabolite 25-O-desacetylrifabutin.
Samtidig brug af boostet darunavir og kortikosteroider, der metaboliseres via CYP3A (f.eks. fluticasonpropionat eller andre inhalerede eller nasale kortikosteroider) kan øge risikoen for systemiske kortikosteroidbivirkninger, herunder Cushings syndrom og binyresuppression. 
Concomitant use of boosted darunavir and corticosteroids that are metabolised by CYP3A (e.g. fluticasone propionate or other inhaled or nasal corticosteroids) may increase the risk of development of systemic corticosteroid effects, including Cushing's syndrome and adrenal suppression.
Darunavir Krka kan ikke virke korrekt uden ritonavir og mad. 
Darunavir Krka cannot work properly without ritonavir and food.
ETIKET TIL BEHOLDER 
LABEL for bottle
375 mg Darunavir Krka + 50 mg ritonavir to gange dagligt mellem 30 og 40 kg 
375 milligram darunavir + 50 milligram ritonavir twice a day between 30 and 40 kilograms
Post partum (6-12 uger) (n=16) 
Postpartum (6-12 weeks) (n=16)
Anvisninger for børn fra 3 år og opefter med en legemsvægt på mindst 40 kg - Tag hver dag 800 mg Darunavir Krka (2 tabletter a 400 mg Darunavir Krka eller 1 tablet a 800 mg Darunavir Krka) en gang dagligt og på samme tidspunkt. 
Instructions for children 3 years of age and above, weighing more than 40 kilograms Take 800 milligram Darunavir Krka (2 tablets containing 400 milligram of Darunavir Krka or 1 tablet containing 800 milligram of Darunavir Krka) at the same time, once a day, every day.
Darunavir med lavdosis ritonavir med triazolam eller oral midazolam er kontraindiceret (se pkt. 
Darunavir with low dose ritonavir with triazolam or oral midazolam is contraindicated (see section 4.3)
Co-administration af boostet darunavir og sildenafil til behandling af pulmonal arteriel hypertension er derfor kontraindiceret (se pkt. 
Therefore, coadministration of boosted darunavir and sildenafil when used for the treatment of pulmonary arterial hypertension is contraindicated (see section 4.3).
Yderligere bekræftede en farmakokinetisk model og simulering af darunavireksponeringer hos pædiatriske patienter i alderen 3 til <18 år de darunavireksponeringer, som blev observeret i de kliniske studier, og gav mulighed for at fastlægge vægtbaserede doser af darunavir/ritonavir en gang daglig hos pædiatriske patienter med en legemsvægt på mindst 15 kg, som er enten ART-naive eller behandlingserfarne uden DRV-RAMs* og med plasma-hiv-1-RNA <100.000 kopier/ml og CD4+- celletal ≥100 × 10 
In addition, pharmacokinetic modeling and simulation of darunavir exposures in paediatric patients across the ages of 3 to < 18 years confirmed the darunavir exposures as observed in the clinical studies and allowed the identification of weight-based darunavir/ritonavir once daily dosing regimens for paediatric patients weighing at least 15 kg that are either ART-naïve or treatment-experienced paediatric patients without DRV-RAMs* and who have plasma HIV-1 RNA < 100,000 copies/ml and CD4+ cell count ≥ 100 cells x 10
Nevirapin 200 mg to gange daglig nevirapin AUC ↑ 27% nevirapin Cmin ↑ 47% nevirapin Cmax ↑ 18% darunavir: koncentrationerne var i overensstemmelse med historiske data. 
Nevirapine 200 mg twice daily nevirapine AUC ↑ 27% nevirapine Cmin ↑ 47% nevirapine Cmax ↑ 18% darunavir: concentrations were consistent with historical data (↑ nevirapine from CYP3A inhibition)
Dolutegravir dolutegravir AUC ↓ 22% dolutegravir C24h ↓ 38% dolutegravir Cmax ↓ 11% darunavir ↔* 
HIV ANTIRETROVIRALS Integrase strand transfer inhibitors Dolutegravir dolutegravir AUC ↓ 22% dolutegravir C24h ↓38% dolutegravir Cmax ↓ 11% darunavir ↔*
Boostet darunavir kan administreres sammen med H2receptorantagonister uden dosisjusteringer. 
Boosted darunavir can be coadministered with H2-receptor antagonists without dose adjustments.
Du skal altid tage Darunavir Krka med ritonavir og mad. 
Always take with ritonavir and food.
≥30 kg-<40 kg 675 mg darunavir/100 mg ritonavir en gang dagligt 
≥ 30 kg-< 40 kg 675 mg darunavir /100 mg ritonavir once daily
Perphenazin Risperidon Thioridazin Lurasidon Pimozid Sertindol 
Lurasidone Pimozide Sertindole
Darunavir Krka virker ikke korrekt uden mad. 
Darunavir Krka cannot work properly without food.
b 
d
Måske har du brug for en anden dosis af Darunavir Krka, som ikke kan sammensættes med 400 mg eller 800 mg tabletterne. 
You will require a different dose of Darunavir Krka which cannot be administered with these 600 milligram tablets.
Darunavir administreret sammen med lavdosis ritonavir og amiodaron, bepridil, dronedaron, ivabradin, kinidin eller ranolazin er kontraindiceret (se pkt. 
Darunavir co-administered with low dose ritonavir and amiodarone, bepridil, dronedarone, ivabradine, quinidine, or ranolazine is contraindicated (see section 4.3).
Den anbefalede dosis er 600 mg to gange dagligt sammen med ritonavir 100 mg to gange dagligt i forbindelse med et måltid. 
The recommended dose regimen is 600 mg twice daily taken with ritonavir 100 mg twice daily taken with food.
100 mg ritonavir oral opløsnig: 80 mg/ml 
100 milligram ritonavir oral solution: 80 milligram per milliliter
- Buprenorphin/naloxon (medicin til behandling af afhængighed af morfin og lignende). 
Buprenorphine/naloxone (medicines to treat opioid dependence) Salmeterol (medicine to treat asthma)
Darunavir Krka 400 mg og 800 mg tabletter anvendes til at behandle voksne og børn (fra 3 år og opefter med en legemsvægt på mindst 40 kg), som er smittet med hiv, og - som ikke før har fået medicin til behandling af hiv - hos nogle patienter, som før har fået medicin til behandling af hiv (din læge vil afgøre dette). 
The Darunavir Krka 400 and 800 milligram tablets are used to treat adults and children (3 years of age and above, at least 40 kilograms body weight) who are infected by HIV and who have not used antiretroviral medicines before.
Samtidig anvendelse af colchicin og darunavir administreret sammen med lavdosis ritonavir kan øge eksponeringen for colchicin. 
Concomitant use of colchicine and darunavir co-administered with low dose ritonavir may increase the exposure to colchicine.